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post-procedural period. Further study is warranted to investigate a strategy
of administration of c7E3 after coronary dissection has occurred.
were examined with univariate followed by stepwise multivariate regression
analysis.
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Heparin Dosing Nomogram
Correlates of Acute Myocardial Infarction (AMI)
After Successful Coronary Angloplasty (PTCA)
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Patient Weight (kg)
Univariate Multivariate
critical value p-value critical value p·value
Age 0034 ns
Weight -2.15 0.033 -2925 <0.001
Female Gender 121 0.34
Unstable Angina -2.04 0.043 -0.069 ns
Pre-procedural IV Heparin -538 <0.001 -2.39 0023
Heparin Dose 635 <0.001 8.95 <0.001
95
90
100 --.-------,
Chi SO ODDS Ratio p Value
Previous MI 37 149 <0.0001
Angina Class III-IV 20 1.17 <0.0001
Diabetes 13 146 <0.0001
Multivessel CAD 11 1.26 0.001
Age 8 0.98 0.004
CHF 5 134 0024
Conclusions: Patient weight, pre-procedural IV heparin therapy, and hep-
arin dose were significant independent predictors of the ACT achieved, Pre-
procedural intravenous heparin significantly increased the heparin dose re-
quired to achieve the target ACT, suggesting the development of tolerance
to heparin. Similarly, patients with unstable angina required significantly
more heparin to achieve the target ACT Recognition of these factors allows
patient-specific heparin dosing during angioplasty. A nomogram for patients
receiving pre-procedural heparin therapy, for example, shows the relation-
ship between patient weight. heparin dose, and the expected target ACT.
In long term follow up after successful angioplasty, the presence of these
co-morbid illnesses may help in identifying the patients at higher risk of hav-
ing AMI after successful angioplasty, This risk stratification strategy may in-
fluence survival after angioplasty.
Rizwan A Karatela, William S. Weintraub, John S, Douglas Jr, Spencer B. King III.
Emory University School of Medicine, Atlanta, GA
To identify the factors predicting AMI after PTCAwe studied 10,772 patients
who had successful PTCA at our institution. 880 patients had AMI following
discharge while 8.754 patients remained AMI free during long term follow up
after successful uncomplicated PTCA While there was no difference in the 5
year freedom from AMI based on sex, presence of hypertension or LVH, the
freedom from AMI was lower in patients with previous MI (84% vs 91 %, P
= < 0.0001), diabetes (84% vs 90%, p = < 0,0001). angina class III-IV (87%
vs 91 %, P ~ < 0.0001), and CHF (85% vs 89%, P = 0.014). The multivariate
correlates of AM I were:
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A New Low Cost Protocol for Elective PTCA
Preconditioning Human Myocardium -
Reduced Hypoxanthine Production During PTCA
Patient-Specific Heparin Dosing During
Angioplasty
Pts LOS Campi Costs ($) Savings
Lab Room Total
Prepath 819 2.1 1.6% 2,670 825 3.495
Path "p;' 115 104 0.9% 2,582 590 3,172 9.2%
Path "B" 227 1.28 0.9% 2,654 643 3,297 5.7%
Mark Nootens, Joseph Condon, Greg Elsner, Brenda Erner, Ronald Landin,
Charles Orr, James Hermiller, Cass Pinkerton, Thomas Linnemeier. The Indiana
Heart Institute, Indianapolis, IN
In order to curb costs, 2 protocols for elective PTCA were developed. Path
"/Ji' pts had sheath removal ASAP following PTCA (when ACT < 1501 and
discharge after 12 hrs IV heparin. Path "B" pts had overnight heparin with
sheath removal the following morning. "/Ji' pts had no venous sheath, type
and screen, IV NTG or labs except PH drawn post PTCA. "B" pts had a
venous sheath, type and screen, IV NTG and labs drawn post PTCA (lytes,
BUN/creat, CPKx3). Unstable angina, acute MI, staged PTCA or stents were
excluded. "/Ji' or "B" was used for elective PTCA, at the discretion of the an-
giographer, from 7/93-7/94 and compared to prior elective PTCA, 7/92-7/93
(prepathl
Conclusion: In elective PTCA costs are reduced safely by discharge the
next day (path "B") and further in selected pts by using a new low cost pro-
tocol (path "/Ji'). Additional savings might be appreciated if these pts were
observed in a less intense setting after sheath removal.
LOS = length of stay (days), Campi = death, MI, CVA or hematoma requiring vascular
repair or transfusion. Lab = cath lab. supplies and blood work costs, Room = PTCA unit
and telemetry costs
Hypoxanthine release is reduced after second and third prolonged balloon
inflations when compared to the first shorter inflation reflecting an adaptive
response of the myocardium to ischaemia. These results show metabolic
evidence for preconditioning in the human myocardium.
Hypoxanthine
(flmolesAitre of blood) -001 ± 0.37 -3.41 ± 2.05 -1.54 ± 0.64 -242 ± 0.56
Nigel Jepson, Kameljit Kalsl 1, Richard Cowell, Vincent Paul, Charles Iisley,
Anne-Marie Seymour 1. Dept. of Cardiology, NHU, Harefield Hospital, Middlesex, UK.;
1 Dept of Cardiothoracic Surgery. NHU, Harefield Hospital, Middlesex, UK.
Brief episodes of myocardial ischaemia and reperfusion protect against sub-
sequent prolonged ischaemic insults. This adaptive response termed pre-
conditioning has been observed with successive coronary occlusions at
PTCA based on recordings of anginal intensity and ECG changes. The aim of
this study was to evaluate myocardial release of Hypoxanthine (HXllan ATP
catabolite and a sensitive marker of ischaemia) in coronary sinus blood im-
mediately after successive balloon inflations. Nine male patients mean age
50 ± 2.1 with isolated left anterior descending artery stenoses and normal
left ventricular function were studied. Collateral channels filling diseased ar-
terial segment were absent on the diagnostic angiogram, PTCA consisted
of three balloon inflations, durations of which were: (1) 60-90 seconds, (21
90-180 seconds, (3) 180-300 seconds with 5 minutes of intervening reper-
fusion between each. Paired aortic and coronary sinus blood samples were
taken immediately after each deflation and deproteinized with 1.3 M HCI04
and neutralized supernatant fractions analysed by HPLC for HX content. The
arteriovenous differences (mean ± SEM) were:
William B. Hillegass, Brigit1a C. Brott. Eric B. Haura, Robert A. Harrington, Harry
R. Phillips, Richard S. Stack, Robert M. Califf. Duke Hospital, Durham, NC
The risk of ischemic events and bleeding complications during angioplasty
is related to the intensity of heparin anticoagulation as monitored by the
activated clotting time (ACT). Data on patient characteristics that affect the
dosing of heparin during angioplasty to achieve a desired target ACT is lim-
ited. The Hemochron ACT was measured 10 minutes after a heparin bolus
in 438 non-emergency angioplasty patients. The influence of heparin dose,
patient age, weight. gender, presenting diagnosis, and pre-procedural con-
tinuous intravenous heparin use on the intensity of anticoagulation achieved
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